actabiomedicaActa Biomedica ScientificaActa Biomedica Scientifica2541-94202587-9596Scientific Centre for Family Health and Human Reproduction Problems10.29413/ABS.2018-3.4.11actabiomedica-652Research ArticleОНКОЛОГИЯONCOLOGYЛЕКТИНЫ В АНТИРАКОВЫХ СТРАТЕГИЯХLECTINS IN ANTI-CANCER STRATEGIESЛахтинМ. В.LakhtinM. V.

125212, г. Москва, ул. Адмирала Макарова, 10, Россия

кандидат биологических наук, старший научный сотрудник, ФБУН «Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского» Роспотребнадзора

 тел. (495) 452-18-16

ul. Admirala Makarova 10, Moscow 125212, Russian Federation

Candidate of Medical Sciences, Senior Research Officer, G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology 

tel. (495) 708-02-62

info@gabrich.comЛахтинВ. М.LakhtinV. M.

125212, г. Москва, ул. Адмирала Макарова, 10, Россия

доктор биологических наук, главный научный сотрудник, ФБУН «Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского» Роспотребнадзора

тел. (495) 452-18-16

ul. Admirala Makarova 10, Moscow 125212, Russian Federation

Doctor of Medical Sciences, Chief Research Officer, G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology

tel. (495) 452-18-16

АлёшкинВ. А.AleshkinV. A.

125212, г. Москва, ул. Адмирала Макарова, 10, Россия

доктор биологических наук, профессор, заместитель директора, ФБУН «Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского» Роспотребнадзора

ul. Admirala Makarova 10, Moscow 125212, Russian Federation

Doctor of Medical Sciences, Professor, Deputy Director, G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology

https://orcid.org/0000-0003-4061-1407АфанасьевМ. С.AfanasievM. S.

119435, г. Москва, ул. Большая Пироговская, 2, стр. 2, Россия

доктор медицинских наук, доцент кафедры клинической аллергологии и иммунологии, ФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России

тел. (499) 506-69-68

ul. Bol’shaya Pirogovskaya 2, str. 2, Moscow 119435, Russian Federation

Doctor of Medical Sciences, Associate Professor at the Department of Clinical Allergology and Immunology, The First Sechenov Moscow State Medical University 

tel. (499) 506-69-68

mafa78@inbox.ruhttps://orcid.org/0000-0001-6497-1795АфанасьевС. С.AfanasievS. S.

125212, г. Москва, ул. Адмирала Макарова, 10, Россия

доктор медицинских наук, профессор, заместитель директора, ФБУН «Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского» Роспотребнадзора

ul. Admirala Makarova 10, Moscow 125212, Russian Federation

Doctor of Medical Sciences, Professor, Deputy Director, G.N. Gabrichevsky Research Institute for Epidemiology and Microbiology

ФБУН «Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского» РоспотребнадзораG.N. Gabrichevsky Research Institute for Epidemiology and MicrobiologyФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава РоссииThe First Sechenov Moscow State Medical University201828072018346977Copyright © Лахтин М.В., Лахтин В.М., Алёшкин В.А., Афанасьев М.С., Афанасьев С.С., 20182018Лахтин М.В., Лахтин В.М., Алёшкин В.А., Афанасьев М.С., Афанасьев С.С.Lakhtin M.V., Lakhtin V.M., Aleshkin V.A., Afanasiev M.S., Afanasiev S.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.actabiomedica.ru/jour/article/view/652

Проведён анализ литературы, преимущественно 2016–2017 гг., рассматривающей роль лектиновых паттерн-распознающих рецепторов в противоопухолевом иммунитете человека.  Отмечены наиболее часто используемые рецепторные лектины в разработке  противоопухолевых процедур, стратегий и потенциальных вакцин. Приведены примеры  применения лектин-паттерновых (над)молекулярных и клеточных взаимоотношений в  изучении связанных с кровью опухолей (лейкемий, лимфом, миеломы, других), солидных  опухолей (рака яичника, шейки матки, простаты, мочевого пузыря, поджелудочной железы,  кишечника, печени, почек, груди, кожи, других) и раковых клеточных линий. Отмечены  основные антираковые стратегии с участием коммуникационных лектинов. Регуляция  экспрессии различающихся лектинов и их взаимодействия с гликоконъюгатными  паттернами, а также распределения сочетаний лектинов и антигенов CD между  субпопуляциями антиген-презентирующих клеток (дендритных клеток cDC, mDC, moDC,  pDC, макрофагов М2 и М1), М-клеток слизистой, природных киллерных лимфоцитов являются важным для усиления ответов врождённого и сцепленного с ним  адаптивного иммунитетов. Оценены перспективы зависимых от лектинов (рецепторных и  растворимых) коммуникаций, обусловленных целевым действием (распознаванием и  инициацией дальнейших каскадов событий – внутриклеточных и межклеточных)  гликоконъюгатных паттернов в клетки врождённого иммунитета для лечения рака и разработки антираковых вакцин.

The published during last few years data concerning communicative role of lectins (proteins and their complexes which recognize  carbohydrates, glycoconjugates and their patterns) in on-duty  supporting and increasing anticancer status of human immunity are  analyzed. Examples of lectin-(glycoconjugate pattern) strategies,  approaches and tactic variants in study and development of  anticancer treatments, principle variants of therapy, possible  vaccines in 35 cases of blood connected tumors (leukemia,  lymphomas, others), solid tumors (carcinomas, sarcoma, cancers of vaginal biotopes, prostate, bladder, colon, other intestinal  compartments, pancreas, liver, kidneys, others) and cancer cell lines  are described and systemized. The list of mostly used communicative lectins (pattern recognition receptors, their soluble forms, other  soluble lectins possessing specificities of importance) involving in key intercellular cascades and pathway co-functioning is presented. The  regulation of resulting expression of distinct active lectins (available and hetero/di/oligomeric forms) and their interaction to  adequate glycoconjugate patterns as well as influence distribution of  co-functioning lectins and antigens CD between populations and  subpopulations of antigen-presented cells (dendritic cells cDC, mDC,  moDC, pDC; macrophages M2 and M1), mucosal M-cells, NK-cells  play key role for choice and development of anticancer complex  procedures increasing innate and innate-coupled immune responses.  Prospects of (receptor lectin)-dependent intercellular  communications and targeting glycoconjugate constructions into  innate immunity cells for therapy of cancer and development of anticancer vaccines are evaluated and discussed.

злокачественные опухолилектиныгликоконъюгатыадъювантыдендритные клеткимакрофагиМ-клеткиNK-клеткиврождённый иммунитетсубпопуляции клетокмежклеточные коммуникацииантираковая терапияантираковые вакциныmalignant tumorsreceptor lectinsglycoconjugatesadjuvantscell targetingdendritic cellsmacrophagesM-cellsNK-cellscell subpopulationsinnate immunityanticancer therapyanticancer v accinesReferencesЛахтин М.В., Лахтин В.М., Афанасьев С.С., Алешкин В.А. Лектины: перспективы в иммунологии, микробиологии и биотехнологии // Уральский научный вестник. – 2017. – Т. 3, № 12. – С. 25–47. Lakhtin MV, Lakhtin VM, Afanasiev SS, Aleshkin VA. (2017). Lectins: prospects in immunology, microbiology and biotechnology [Lektiny: perspektivy v immunologii, mikrobiologii i biotekhnologii]. Ural’skiy nauchnyy vestnik, 3 (12), 25-47.Лахтин М.В., Лахтин В.М., Афанасьев С.С., Алешкин В.А. Лектины: перспективы в иммунологии, микробиологии и биотехнологии // Уральский научный вестник. – 2017. – Т. 3, № 12. – С. 25–47. Lakhtin MV, Lakhtin VM, Afanasiev SS, Aleshkin VA. (2017). Lectins: prospects in immunology, microbiology and biotechnology [Lektiny: perspektivy v immunologii, mikrobiologii i biotekhnologii]. Ural’skiy nauchnyy vestnik, 3 (12), 25-47.Лахтин М.В., Лахтин В.М., Афанасьев С.С., Байракова А.Л., Алешкин В.А., Афанасьев М.С. Кандидные маркеры болезней урогенитальных биотопов: реактивность к лектинам пробиотиков // Acta Biomedica Scientifica. – 2018. – Т. 3, № 1. – С. 49–53. DOI: 10.29413/ABS.2018-3.1.7 Lakhtin MV, Lakhtin VM, Afanasiev SS, Bayrakova AL, Aleshkin VA, Afanasiev MS. (2018). Candida markers of urogenital biotopes diseases: reactivity to lectins of probiotics [Kandidnye markery bolezney urogenital’nykh biotopov: reaktivnost’ k lektinam probiotikov]. Acta Biomedica Scientifica, 3 (1), 49-53. DOI: 10.29413/ABS.2018-3.1.7Лахтин М.В., Лахтин В.М., Афанасьев С.С., Байракова А.Л., Алешкин В.А., Афанасьев М.С. Кандидные маркеры болезней урогенитальных биотопов: реактивность к лектинам пробиотиков // Acta Biomedica Scientifica. – 2018. – Т. 3, № 1. – С. 49–53. DOI: 10.29413/ABS.2018-3.1.7 Lakhtin MV, Lakhtin VM, Afanasiev SS, Bayrakova AL, Aleshkin VA, Afanasiev MS. (2018). Candida markers of urogenital biotopes diseases: reactivity to lectins of probiotics [Kandidnye markery bolezney urogenital’nykh biotopov: reaktivnost’ k lektinam probiotikov]. Acta Biomedica Scientifica, 3 (1), 49-53. DOI: 10.29413/ABS.2018-3.1.7Alves AM, Diel LF, Lamers ML. (2017). Macrophages and prognosis of oral squamous cell carcinoma: a systematic review. J Oral Pathol Med, 47 (5), 460-467. DOI: 10.1111/jop.12643Alves AM, Diel LF, Lamers ML. (2017). Macrophages and prognosis of oral squamous cell carcinoma: a systematic review. J Oral Pathol Med, 47 (5), 460-467. DOI: 10.1111/jop.12643Andersen MN, Andersen NF, Rødgaard-Hansen S, Hokland M, Abildgaard N, Møller HJ. (2015). The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): implications in multiple myeloma. Leuk Res, 39 (9), 971-975. DOI: 10.1016/j.leukres.2015.06.003Andersen MN, Andersen NF, Rødgaard-Hansen S, Hokland M, Abildgaard N, Møller HJ. (2015). The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): implications in multiple myeloma. Leuk Res, 39 (9), 971-975. DOI: 10.1016/j.leukres.2015.06.003Boeck CL, Amberger DC, Doraneh-Gard F, Sutanto W, Guenther T, Schmohl J, Schuster F, Salih H, Babor F, Borkhardt A, Schmetzer H. (2017). Significance of frequencies, compositions, and/or antileukemic activity of (DC-stimulated) invariant NKT, NK and CIK cells on the outcome of patients with AML, ALL and CLL. J Immunother, 40 (6), 224-248. DOI: 10.1097/CJI.0000000000000171Boeck CL, Amberger DC, Doraneh-Gard F, Sutanto W, Guenther T, Schmohl J, Schuster F, Salih H, Babor F, Borkhardt A, Schmetzer H. (2017). Significance of frequencies, compositions, and/or antileukemic activity of (DC-stimulated) invariant NKT, NK and CIK cells on the outcome of patients with AML, ALL and CLL. J Immunother, 40 (6), 224-248. DOI: 10.1097/CJI.0000000000000171Caley MP, King H, Shah N, Wang K, Rodriguez-Teja M, Gronau JH, Waxman J, Sturge J. (2016). Tumor-associated Endo180 requires stromal-derived LOX to promote metastatic prostate cancer cell migration on human ECM surfaces. Clin Exp Metastasis, 33 (2), 151-165. DOI: 10.1007/s10585-015-9765-7Caley MP, King H, Shah N, Wang K, Rodriguez-Teja M, Gronau JH, Waxman J, Sturge J. (2016). Tumor-associated Endo180 requires stromal-derived LOX to promote metastatic prostate cancer cell migration on human ECM surfaces. Clin Exp Metastasis, 33 (2), 151-165. DOI: 10.1007/s10585-015-9765-7Cordeau M, Belounis A, Lelaidier M, Cordeiro P, Sartelet H, Herblot S, Duval M. (2016). Efficient killing of high risk neuroblastoma using natural killer cells activated by plasmacytoid dendritic cells. PLoS One, 11 (10), e0164401. DOI: 0.1371/journal.pone.0164401Cordeau M, Belounis A, Lelaidier M, Cordeiro P, Sartelet H, Herblot S, Duval M. (2016). Efficient killing of high risk neuroblastoma using natural killer cells activated by plasmacytoid dendritic cells. PLoS One, 11 (10), e0164401. DOI: 0.1371/journal.pone.0164401Chen C, Li K, Jiang H, Song F, Gao H, Pan X, Shi B, Bi Y, Wang H, Wang H, Li Z. (2017). Development of T cells carrying two complementary chimeric antigen receptors against Glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother, 66 (4), 475-489. DOI: 10.1007/s00262-016-1949-8Chen C, Li K, Jiang H, Song F, Gao H, Pan X, Shi B, Bi Y, Wang H, Wang H, Li Z. (2017). Development of T cells carrying two complementary chimeric antigen receptors against Glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother, 66 (4), 475-489. DOI: 10.1007/s00262-016-1949-8Chowdhury SR, Ray U, Chatterjee BP, Roy SS. (2017). Targeted apoptosis in ovarian cancer cells through mitochondrial dysfunction in response to Sambucus nigra agglutinin. Cell Death Dis, 8 (5), e2762. DOI: 10.1038/cddis.2017.77Chowdhury SR, Ray U, Chatterjee BP, Roy SS. (2017). Targeted apoptosis in ovarian cancer cells through mitochondrial dysfunction in response to Sambucus nigra agglutinin. Cell Death Dis, 8 (5), e2762. DOI: 10.1038/cddis.2017.77Costa F, Vescovini R, Bolzoni M, Marchica V, Storti P, Toscani D , Accardi F , Notarfranchi L, Dalla Palma B, Manferdini C, Manni S, Todaro G, Lisignoli G, Piazza F, Aversa F, Giuliani N. (2017). Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. Oncotarget, 8 (32), 53053-53067. DOI: 10.18632/oncotarget.18085Costa F, Vescovini R, Bolzoni M, Marchica V, Storti P, Toscani D , Accardi F , Notarfranchi L, Dalla Palma B, Manferdini C, Manni S, Todaro G, Lisignoli G, Piazza F, Aversa F, Giuliani N. (2017). Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. Oncotarget, 8 (32), 53053-53067. DOI: 10.18632/oncotarget.18085Daley D, Mani VR, Mohan N, Akkad N, Ochi A, Heindel DW, Lee KB, Zambirinis CP, Pandian GSB, Savadkar S, Torres-Hernandez A, Nayak S, Wang D, Hundeyin M, Diskin B, Aykut B, Werba G, Barilla RM, Rodriguez R, Chang S, Gardner L, Mahal LK, Ueberheide B, Miller G. (2017). Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat Med, 23 (5), 556-567. DOI: 10.1038/nm.4314Daley D, Mani VR, Mohan N, Akkad N, Ochi A, Heindel DW, Lee KB, Zambirinis CP, Pandian GSB, Savadkar S, Torres-Hernandez A, Nayak S, Wang D, Hundeyin M, Diskin B, Aykut B, Werba G, Barilla RM, Rodriguez R, Chang S, Gardner L, Mahal LK, Ueberheide B, Miller G. (2017). Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat Med, 23 (5), 556-567. DOI: 10.1038/nm.4314Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A, Allavena P, Mantovani A, Marchesi F. (2016). Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut, 65 (10), 1710-1720. DOI: 10.1136/gutjnl-2015-309193Di Caro G, Cortese N, Castino GF, Grizzi F, Gavazzi F, Ridolfi C, Capretti G, Mineri R, Todoric J, Zerbi A, Allavena P, Mantovani A, Marchesi F. (2016). Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy. Gut, 65 (10), 1710-1720. DOI: 10.1136/gutjnl-2015-309193Ding D, Song Y, Yao Y, Zhang S. (2017). Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer. Oncol Lett, 14 (3), 2982-2990. DOI: 10.3892/ol.2017.6547Ding D, Song Y, Yao Y, Zhang S. (2017). Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer. Oncol Lett, 14 (3), 2982-2990. DOI: 10.3892/ol.2017.6547van Dinther D, Stolk DA, van de Ven R, van Kooyk Y, de Gruijl TD, den Haan JMM. (2017). Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. J Leukoc Biol, 102 (4), 1017-1034. DOI: 10.1189/jlb.5MR0217-059RRvan Dinther D, Stolk DA, van de Ven R, van Kooyk Y, de Gruijl TD, den Haan JMM. (2017). Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccines. J Leukoc Biol, 102 (4), 1017-1034. DOI: 10.1189/jlb.5MR0217-059RRFaddaoui A, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A. Gobeil S, Morin C, Macdonald E, Vanderhyden B, Bachvarov D. (2016). The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells. Oncotarget, 7 (12), 14125-14142. DOI: 10.18632/oncotarget.7288Faddaoui A, Bachvarova M, Plante M, Gregoire J, Renaud MC, Sebastianelli A. Gobeil S, Morin C, Macdonald E, Vanderhyden B, Bachvarov D. (2016). The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells. Oncotarget, 7 (12), 14125-14142. DOI: 10.18632/oncotarget.7288Feng D, Shaikh AS, Wang F. (2016). Recent advance in tumor-associated carbohydrate antigens (TACAs)- based antitumor vaccines. ACS Chem Biol, 11 (4), 850-863. DOI: 10.1021/acschembio.6b00084Feng D, Shaikh AS, Wang F. (2016). Recent advance in tumor-associated carbohydrate antigens (TACAs)- based antitumor vaccines. ACS Chem Biol, 11 (4), 850-863. DOI: 10.1021/acschembio.6b00084Goswami KK, Ghosh T, Ghosh S, Sarkar M, Bose A, Baral R. (2017). Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Cell Immunol, 316, 1-10. DOI: 10.1016/j.cellimm.2017.04.005Goswami KK, Ghosh T, Ghosh S, Sarkar M, Bose A, Baral R. (2017). Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Cell Immunol, 316, 1-10. DOI: 10.1016/j.cellimm.2017.04.005Haas T, Heidegger S, Wintges A, Bscheider M, Bek S, Fischer JC, Eisenkolb G, Schmickl M, Spoerl S, Peschel C, Poeck H, Ruland J. (2017). Card9 controls dectin-1-induced t-cell cytotoxicity and tumor growth in mice. Eur J Immunol, 47 (5), 872-879. DOI: 10.1002/eji.201646775Haas T, Heidegger S, Wintges A, Bscheider M, Bek S, Fischer JC, Eisenkolb G, Schmickl M, Spoerl S, Peschel C, Poeck H, Ruland J. (2017). Card9 controls dectin-1-induced t-cell cytotoxicity and tumor growth in mice. Eur J Immunol, 47 (5), 872-879. DOI: 10.1002/eji.201646775Hollander N, Haimovich J. (2017). Altered N-linked glycosylation in follicular lymphoma and chronic lymphocytic leukemia: involvement in pathogenesis and potential therapeutic targeting. Front Immunol, 2017 Aug 2; 8: 912. DOI: 10.3389/fimmu.2017.00912Hollander N, Haimovich J. (2017). Altered N-linked glycosylation in follicular lymphoma and chronic lymphocytic leukemia: involvement in pathogenesis and potential therapeutic targeting. Front Immunol, 2017 Aug 2; 8: 912. DOI: 10.3389/fimmu.2017.00912Kang HG, Kim DH, Kim SJ, Cho Y, Jung J, Jang W, Chun KH. (2016). Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. Oncotarget, 7 (42), 68229-68241. DOI: 10.18632/oncotarget.11920Kang HG, Kim DH, Kim SJ, Cho Y, Jung J, Jang W, Chun KH. (2016). Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. Oncotarget, 7 (42), 68229-68241. DOI: 10.18632/oncotarget.11920Kawashima K, Maeda K, Saigo C, Kito Y, Yoshida K, Takeuchi T. (2017). Adiponectin and Intelectin-1: important adipokine players in obesity-related colorectal carcinogenesis. Int J Mol Sci, 2017 Apr 19; 18 (4), pii: E866. DOI: 10.3390/ijms18040866Kawashima K, Maeda K, Saigo C, Kito Y, Yoshida K, Takeuchi T. (2017). Adiponectin and Intelectin-1: important adipokine players in obesity-related colorectal carcinogenesis. Int J Mol Sci, 2017 Apr 19; 18 (4), pii: E866. DOI: 10.3390/ijms18040866Klauber TCB, Laursen JM, Zucker D, Brix S, Jensen SS, Andresen TL. (2017). Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines. Acta Biomater, 53, 367-377. DOI: 10.1016/j.actbio.2017.01.072Klauber TCB, Laursen JM, Zucker D, Brix S, Jensen SS, Andresen TL. (2017). Delivery of TLR7 agonist to monocytes and dendritic cells by DCIR targeted liposomes induces robust production of anti-cancer cytokines. Acta Biomater, 53, 367-377. DOI: 10.1016/j.actbio.2017.01.072Komohara Y, Ohnishi K, Takeya M. (2017). Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses. Cancer Sci, 108 (3), 290-295. DOI: 10.1111/cas.13137Komohara Y, Ohnishi K, Takeya M. (2017). Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses. Cancer Sci, 108 (3), 290-295. DOI: 10.1111/cas.13137Kovaleva OV, Samoilova DV, Shitova MS, Gratchev A. (2016). Tumor associated macrophages in kidney cancer. Anal Cell Pathol (Amst), 2016, 9307549.Kovaleva OV, Samoilova DV, Shitova MS, Gratchev A. (2016). Tumor associated macrophages in kidney cancer. Anal Cell Pathol (Amst), 2016, 9307549.Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, Hampton EN, Rodgers DT, Kim CH, Schultz PG, Young TS. (2017). Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci, 18 (11), 2259. DOI: 10.3390/ijms18112259Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, Hampton EN, Rodgers DT, Kim CH, Schultz PG, Young TS. (2017). Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci, 18 (11), 2259. DOI: 10.3390/ijms18112259Li X. (2016). TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma. Tumour Biol, 37 (4), 5585-5590. DOI: 10.1007/s13277-015-4388-9Li X. (2016). TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma. Tumour Biol, 37 (4), 5585-5590. DOI: 10.1007/s13277-015-4388-9Mattila JP, Mirandola L, Chiriva-Internati M. (2018). Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17. J Biomed Mater Res B Appl Biomater, 4. DOI: 10.1002/jbm.b.34092Mattila JP, Mirandola L, Chiriva-Internati M. (2018). Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17. J Biomed Mater Res B Appl Biomater, 4. DOI: 10.1002/jbm.b.34092McKee SJ, Doff BL, Soon MS, Mattarollo SR. (2017). Therapeutic efficacy of 4-1BB costimulation is abrogated by PD-1 blockade in a model of spontaneous B-cell lymphoma. Cancer Immunol Res, 5 (3), 191-197. DOI: 10.1158/2326-6066.CIR-16-0249McKee SJ, Doff BL, Soon MS, Mattarollo SR. (2017). Therapeutic efficacy of 4-1BB costimulation is abrogated by PD-1 blockade in a model of spontaneous B-cell lymphoma. Cancer Immunol Res, 5 (3), 191-197. DOI: 10.1158/2326-6066.CIR-16-0249Mehta RS, Rezvani K. (2018). Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol, 15 (9), 283. DOI: 10.3389/fimmu.2018.00283Mehta RS, Rezvani K. (2018). Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Front Immunol, 15 (9), 283. DOI: 10.3389/fimmu.2018.00283Montraveta A, Lee-Vergés E, Roldán J, Jiménez L, Cabezas S, Clot G, Pinyol M, Xargay- Torrent S, Rosich L, Arimany-Nardí C, Aymerich M, Villamor N, López-Guillermo A, Pérez- Galán P, Roué G, Pastor-Anglada M, Campo E, López-Guerra M, Colomer D. (2016). CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. Oncotarget, 7 (5), 5507-5520. DOI: 10.18632/oncotarget.6685Montraveta A, Lee-Vergés E, Roldán J, Jiménez L, Cabezas S, Clot G, Pinyol M, Xargay- Torrent S, Rosich L, Arimany-Nardí C, Aymerich M, Villamor N, López-Guillermo A, Pérez- Galán P, Roué G, Pastor-Anglada M, Campo E, López-Guerra M, Colomer D. (2016). CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. Oncotarget, 7 (5), 5507-5520. DOI: 10.18632/oncotarget.6685Monzavi-Karbassi B, Jousheghany F, Kieber-Emmons T. (2016). Tumor-associated glycans and tregs in immunogenicity of an autologous cell-based vaccine. Immunol Invest, 19, 1-13.Monzavi-Karbassi B, Jousheghany F, Kieber-Emmons T. (2016). Tumor-associated glycans and tregs in immunogenicity of an autologous cell-based vaccine. Immunol Invest, 19, 1-13.Nan J, Xing YF, Hu B, Tang JX, Dong HM, He YM, Ruan DY, Ye QJ, Cai JR, Ma XK, Chen J, Cai XR, Lin ZX, Wu XY, Li X. (2017). Endoplasmic reticulum stress induced LOX-1+ CD15+ polymorphonuclear myeloid-derived suppressor cells in hepatocellular carcinoma. Immunology, 154 (1), 144-155. DOI: 10.1111/imm.12876Nan J, Xing YF, Hu B, Tang JX, Dong HM, He YM, Ruan DY, Ye QJ, Cai JR, Ma XK, Chen J, Cai XR, Lin ZX, Wu XY, Li X. (2017). Endoplasmic reticulum stress induced LOX-1+ CD15+ polymorphonuclear myeloid-derived suppressor cells in hepatocellular carcinoma. Immunology, 154 (1), 144-155. DOI: 10.1111/imm.12876Natoni A, Smith TAG, Keane N, McEllistrim C, Connolly C, Jha A, Andrulis M, Ellert E, Raab MS, Glavey SV, Kirkham-McCarthy L, Kumar SK, Locatelli-Hoops SC, Oliva I, Fogler WE, Magnani JL, O’Dwyer ME. (2017). E-selectin ligands recognized by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. Leukemia, 31 (12), 2642-2651. DOI: 10.1038/leu.2017.123Natoni A, Smith TAG, Keane N, McEllistrim C, Connolly C, Jha A, Andrulis M, Ellert E, Raab MS, Glavey SV, Kirkham-McCarthy L, Kumar SK, Locatelli-Hoops SC, Oliva I, Fogler WE, Magnani JL, O’Dwyer ME. (2017). E-selectin ligands recognized by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271. Leukemia, 31 (12), 2642-2651. DOI: 10.1038/leu.2017.123Rodriguez MC, Yongye AB, Cudic M, Martinez Mayorga K, Liu E, Mueller BM, Ainsley J, Karabencheva-Christova T, Christov CZ, Cudic M, Cudic P. (2017). Targeting cancer-specific glycans by cyclic peptide lectinomimics. Amino Acids, 49 (11), 1867-1883. DOI: 10.1007/s00726-017-2485-3Rodriguez MC, Yongye AB, Cudic M, Martinez Mayorga K, Liu E, Mueller BM, Ainsley J, Karabencheva-Christova T, Christov CZ, Cudic M, Cudic P. (2017). Targeting cancer-specific glycans by cyclic peptide lectinomimics. Amino Acids, 49 (11), 1867-1883. DOI: 10.1007/s00726-017-2485-3Roperto S, Russo V, Esposito I, Ceccarelli DM, Paciello O, Avallone L, Capparelli R, Roperto F. (2015). Mincle, an innate immune receptor, is expressed in urothelial cancer cells of papillomavirus-associated urothelial tumors of cattle. PLoS One, 10 (10), 0141624. DOI: 10.1371/journal.pone.0141624Roperto S, Russo V, Esposito I, Ceccarelli DM, Paciello O, Avallone L, Capparelli R, Roperto F. (2015). Mincle, an innate immune receptor, is expressed in urothelial cancer cells of papillomavirus-associated urothelial tumors of cattle. PLoS One, 10 (10), 0141624. DOI: 10.1371/journal.pone.0141624Sabado RL, Balan S, Bhardwaj N. (2017). Dendritic cell-based immunotherapy. Cell Res, 27 (1), 74-95. DOI: 10.1038/cr.2016.157Sabado RL, Balan S, Bhardwaj N. (2017). Dendritic cell-based immunotherapy. Cell Res, 27 (1), 74-95. DOI: 10.1038/cr.2016.157Saluja SS, Hanlon DJ, Sharp FA, Hong E, Khalil D, Robinson E, Tigelaar R, Fahmy TM, Edelson RL. (2014). Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen. Int J Nanomedicine, 9, 5231-5146. DOI: 10.2147/IJN.S66639Saluja SS, Hanlon DJ, Sharp FA, Hong E, Khalil D, Robinson E, Tigelaar R, Fahmy TM, Edelson RL. (2014). Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen. Int J Nanomedicine, 9, 5231-5146. DOI: 10.2147/IJN.S66639Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD. (2015). Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: Recruitment and activation of BDCA3/CD141+ dendritic cells and enhanced cross-presentation. Cancer Immunol Res, 3 (5), 495-505. DOI: 10.1158/2326-6066.CIR-14-0165Sluijter BJ, van den Hout MF, Koster BD, van Leeuwen PA, Schneiders FL, van de Ven R, Molenkamp BG, Vosslamber S, Verweij CL, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD. (2015). Arming the melanoma sentinel lymph node through local administration of CpG-B and GM-CSF: Recruitment and activation of BDCA3/CD141+ dendritic cells and enhanced cross-presentation. Cancer Immunol Res, 3 (5), 495-505. DOI: 10.1158/2326-6066.CIR-14-0165Song JX, Dian ZJ, Wen Y, Mei F, Li RW, Sa YL. (2016). Assessment of the number and phenotype of macrophages in the human BMB samples of CML. Biomed Res Int, 2016, 8086398. DOI: 10.1155/2016/8086398Song JX, Dian ZJ, Wen Y, Mei F, Li RW, Sa YL. (2016). Assessment of the number and phenotype of macrophages in the human BMB samples of CML. Biomed Res Int, 2016, 8086398. DOI: 10.1155/2016/8086398Strömvall K, Sundkvist K, Ljungberg B, Halin Bergström S, Bergh A. (2017). Reduced number of CD169+ macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients. Prostate, 77 (15), 1468-1477. DOI: 10.1002/pros.23407Strömvall K, Sundkvist K, Ljungberg B, Halin Bergström S, Bergh A. (2017). Reduced number of CD169+ macrophages in pre-metastatic regional lymph nodes is associated with subsequent metastatic disease in an animal model and with poor outcome in prostate cancer patients. Prostate, 77 (15), 1468-1477. DOI: 10.1002/pros.23407Sturge J. (2016). Endo180 at the cutting edge of bone cancer treatment and beyond. J Pathol, 238 (4), 485-488. DOI: 10.1002/path.4673Sturge J. (2016). Endo180 at the cutting edge of bone cancer treatment and beyond. J Pathol, 238 (4), 485-488. DOI: 10.1002/path.4673Tawde SA, Chablani L, Akalkotkar A, D’Souza MJ. (2016). Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery. J Control Release, 235, 147-154. DOI: 10.1016/j.jconrel.2016.05.058Tawde SA, Chablani L, Akalkotkar A, D’Souza MJ. (2016). Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery. J Control Release, 235, 147-154. DOI: 10.1016/j.jconrel.2016.05.058Thordardottir S, Schaap N, Louer E, Kester MG, Falkenburg JH, Jansen J, Radstake TR, Hobo W, Dolstra H. (2017). Hematopoietic stem cell-derived myeloid and plasmacytoid DC- based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo. Oncoimmunology, 6 (3), 1285991. DOI: 10.1080/2162402X.2017.1285991Thordardottir S, Schaap N, Louer E, Kester MG, Falkenburg JH, Jansen J, Radstake TR, Hobo W, Dolstra H. (2017). Hematopoietic stem cell-derived myeloid and plasmacytoid DC- based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo. Oncoimmunology, 6 (3), 1285991. DOI: 10.1080/2162402X.2017.1285991Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, , Xu L, Liao S, Liu W, Wang Y, Liu N, Zhang J, Xia X, Kang T, Chen G, Cai X, Yang H, Zhang X, Lu Y, Zhou P. (2018). CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol, 11 (1), 7. DOI: 10.1186/s13045-017-0553-5Wang J, Chen S, Xiao W, Li W, Wang L, Yang S, , Xu L, Liao S, Liu W, Wang Y, Liu N, Zhang J, Xia X, Kang T, Chen G, Cai X, Yang H, Zhang X, Lu Y, Zhou P. (2018). CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol, 11 (1), 7. DOI: 10.1186/s13045-017-0553-5Wang L, Yin J, Wang X, Shao M, Duan F, Wu W, Peng P, Jin J, Tang Y, Ruan Y, Sun Y, Gu J. (2016). C-type lectin-like receptor 2 suppresses AKT signaling and invasive activities of gastric cancer cells by blocking expression of phosphoinositide 3-kinase subunits. Gastroenterology, 150 (5), 1183-1195.e16. DOI: 10.1053/j.gastro.2016.01.034Wang L, Yin J, Wang X, Shao M, Duan F, Wu W, Peng P, Jin J, Tang Y, Ruan Y, Sun Y, Gu J. (2016). C-type lectin-like receptor 2 suppresses AKT signaling and invasive activities of gastric cancer cells by blocking expression of phosphoinositide 3-kinase subunits. Gastroenterology, 150 (5), 1183-1195.e16. DOI: 10.1053/j.gastro.2016.01.034Weng TY, Li CJ, Li CY, Hung YH, Yen MC, Chang YW, Chen YH, Chen YL, Hsu HP, Chang JY1, Lai MD. (2017). Skin delivery of Clec4a small hairpin RNA elicited an effective antitumor response by enhancing CD8+ immunity in vivo. Mol Ther Nucleic Acids, 9, 419-427. DOI: 10.1016/j.omtn.2017.10.015Weng TY, Li CJ, Li CY, Hung YH, Yen MC, Chang YW, Chen YH, Chen YL, Hsu HP, Chang JY1, Lai MD. (2017). Skin delivery of Clec4a small hairpin RNA elicited an effective antitumor response by enhancing CD8+ immunity in vivo. Mol Ther Nucleic Acids, 9, 419-427. DOI: 10.1016/j.omtn.2017.10.015Yin W, Duluc D, Joo H, Oh S. (2016). dendritic cell targeting vaccine for HPV-associated cancer. Cancer Cell Microenviron, 3 (4), 1482. Epub 2017 Jan 15.Yin W, Duluc D, Joo H, Oh S. (2016). dendritic cell targeting vaccine for HPV-associated cancer. Cancer Cell Microenviron, 3 (4), 1482. Epub 2017 Jan 15.Zhang A, Qian Y, Ye Z, Chen H, Xie H, Zhou L, Shen Y, Zheng S. (2017). Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. Cancer Med, 6 (2), 463-470. DOI: 10.1002/cam4.993Zhang A, Qian Y, Ye Z, Chen H, Xie H, Zhou L, Shen Y, Zheng S. (2017). Cancer-associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma. Cancer Med, 6 (2), 463-470. DOI: 10.1002/cam4.993

The authors declare that there are no conflicts of interest present.